title: Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece.
abstract: OBJECTIVE
  We aimed to estimate the total mean annual treatment cost of different therapy options for patients with moderate-to-severe rheumatoid arthritis (RA) in Greece.
  
  
  METHODS
  A cost-minimization approach was adopted. An economic model was developed to estimate the direct costs of the three widely used treatments within a 1-year time horizon, from a health care payer perspective, either for new or for existing patients. Data on resource use, dose escalation, and frequency of therapy were based on a nationwide field survey of rheumatologists. Other analyses were also undertaken based on evidence from the literature. Total cost comprised the cost of drugs, administration, and hospital day care visits. Unit cost data were obtained from the price bulletin and the government gazettes issued by the Ministry of Health. Due to the short time horizon of the study, the cost was not discounted.
  
  
  RESULTS
  The mean annual total cost per new (or per existing) responder patient on etanercept was estimated at €9,845 (€9,840), and the total cost on etanercept/methotrexate (MTX) was estimated at €9,857 (€9,852). Therapy with etanercept had lower annual cost relative to adalimumab and infliximab. On an annual basis, it was estimated that the difference between etanercept monotherapy and adalimumab monotherapy was €544 (€1,323). Similarly, the difference between etanercept/MTX and infliximab/MTX was €1,871 (€1,490) and €543 (€1,323), respectively, relative to adalimumab/MTX. Results remained constant under other scenario analyses undertaken.
  
  
  CONCLUSIONS
  In the real-life practice setting in Greece, where dose intensity and frequency differences occur, etanercept alone or in combination with MTX, if prescribed as per label, represents the option with lower annual cost per patient when compared with adalimumab or infliximab in patients with RA. These results hold true as long as the assumptions and data used in the analysis remain stable and may alter if any of the underlying parameters, such as drug price, change.
authors: National School of Public Health, Athens, Greece.
authors: Vasilis
authors: V
authors: Fragoulakis
authors: Pfizer Hellas, Athens, Greece.
authors: Elli
authors: E
authors: Vitsou
authors: Pfizer Hellas, Athens, Greece.
authors: Ana Cristina
authors: AC
authors: Hernandez
authors: National School of Public Health, Athens, Greece.
authors: Nikolaos
authors: N
authors: Maniadakis
keywords: dose escalation; economic analysis; etanercept
references: Ann Rheum Dis. 2007 Sep;66(9):1233-8
references: 17392352
references: Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):455-68
references: 23977974
references: J Rheumatol. 2006 Dec;33(12):2398-408
references: 17225293
references: Clin Ther. 2009 Apr;31(4):825-35
references: 19446156
references: Value Health. 2014 Jan-Feb;17(1):5-14
references: 24438712
references: J Pharm Pharm Sci. 2012;15(3):355-60
references: 22974785
references: Adv Ther. 2012 Jul;29(7):620-34
references: 22843208
references: Br J Rheumatol. 1998 Aug;37(8):837-47
references: 9734674
references: Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S107-11
references: 23078839
references: Int J Immunopathol Pharmacol. 2010 Jul-Sep;23(3):783-90
references: 20943048
references: Lancet. 2010 Sep 25;376(9746):1094-108
references: 20870100
references: Arthritis Rheum. 1978 Sep-Oct;21(7):827-33
references: 100122
references: J Med Econ. 2012;15(4):635-43
references: 22332705
references: Health Technol Assess. 2006 Nov;10 (42):iii-iv, xi-xiii, 1-229
references: 17049139
references: Lancet. 2011 Oct 22;378(9801):1457-8
references: 21988763
references: Curr Med Res Opin. 2010 Jul;26(7):1637-45
references: 20429830
references: Best Pract Res Clin Rheumatol. 2012 Oct;26(5):659-76
references: 23218430
references: Arthritis Care Res (Hoboken). 2010 Sep;62(9):1335-41
references: 20506128
references: J Manag Care Pharm. 2006 Sep;12 (7):555-69
references: 16981801
references: Clin Med Insights Arthritis Musculoskelet Disord. 2013 Aug 08;6:35-43
references: 23997576
references: Rheumatol Int. 2014 Jan;34(1):25-33
references: 24057144
references: Curr Med Res Opin. 2013 May;29(5):561-8
references: 23489410
references: Arthritis Rheum. 2008 Jun 15;59(6):762-84
references: 18512708
references: J Rheumatol. 1997 Jun;24(6):1051-60
references: 9195508
references: Arthritis Rheum. 1986 May;29(5):614-9
references: 3718553
references: Am J Health Syst Pharm. 2010 Aug;67(15):1281-7
references: 20651319
references: Drugs. 2005;65(4):473-96
references: 15733011
references: Arthritis Rheum. 1999 Jun;42(6):1209-18
references: 10366114
references: Rheumatology (Oxford). 2007 Mar;46(3):529-32
references: 17012439
references: Arthritis Rheum. 1986 Apr;29(4):488-93
references: 3707626
references: Arthritis Rheum. 1984 May;27(5):522-9
references: 6721884
references: Rheumatology (Oxford). 2006 Dec;45(12):1549-54
references: 16690763
references: Curr Med Res Opin. 2012 Apr;28(4):569-80
references: 22236091
references: Rheumatology (Oxford). 2005 Jul;44(7):932-8
references: 15840597
references: Arthritis Care Res (Hoboken). 2012 May;64(5):625-39
references: 22473917
references: J Rheumatol. 2003 Jul;30(7):1589-601
references: 12858464
references: Clin Exp Rheumatol. 2011 Jan-Feb;29(1):26-34
references: 21345289
references: Clin Rheumatol. 2011 Mar;30 Suppl 1:S3-8
references: 21359507
references: Arthritis Res Ther. 2004;6(4):R315-25
references: 15225367
references: J Med Econ. 2013 Sep;16(9):1120-8
references: 23808901
references: Clin Exp Rheumatol. 2013 Jul-Aug;31(4):559-65
references: 23710583
references: J Rheumatol. 1997 Apr;24(4):719-25
references: 9101508
references: Health Technol Assess. 2011 Mar;15(14 ):1-278
references: 21439251
references: Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S72-84
references: 23072761
references: Adv Ther. 2013 May;30(5):517-27
references: 23740359
references: Arthritis Rheum. 2001 Mar;44(3):528-34
references: 11263766
references: J Med Econ. 2013;16(3):391-6
references: 23298329
references: Semin Arthritis Rheum. 2014 Feb;43(4):447-57
references: 24012040
references: Acta Orthop Scand. 1992 Apr;63(2):207-12
references: 1590060
references: Bull World Health Organ. 2003;81(9):646-56
references: 14710506
references: Clin Rheumatol. 2011 Mar;30 Suppl 1:S33-9
references: 21350796